Monopar Therapeutics Inc (MNPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has a cash flow conversion efficiency ratio of -0.026x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.47 Million) by net assets ($135.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Monopar Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Monopar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Monopar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of Monopar Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Monopar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monopar Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Jinyi Media Corp
SHE:002905
|
2.017x |
|
Hunan Huasheng Co Ltd
SHG:600156
|
0.086x |
|
Guangdong Qunxing Toys Joint-Stock Co Ltd
SHE:002575
|
0.008x |
|
Somalogic Inc
NASDAQ:SLGC
|
-0.043x |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
-0.128x |
|
Quadient SA
PA:QDT
|
0.101x |
|
Hyundai Green Food Co. Ltd.
KO:453340
|
0.048x |
|
TCI Co Ltd
TWO:8436
|
0.026x |
Annual Cash Flow Conversion Efficiency for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Monopar Therapeutics Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Monopar Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $137.83 Million | $-12.20 Million | -0.089x | +23.92% |
| 2024-12-31 | $55.04 Million | $-6.40 Million | -0.116x | +91.73% |
| 2023-12-31 | $5.59 Million | $-7.86 Million | -1.406x | -96.30% |
| 2022-12-31 | $10.09 Million | $-7.23 Million | -0.716x | -85.45% |
| 2021-12-31 | $18.94 Million | $-7.32 Million | -0.386x | -30.03% |
| 2020-12-31 | $15.69 Million | $-4.66 Million | -0.297x | -24.33% |
| 2019-12-31 | $12.63 Million | $-3.02 Million | -0.239x | +42.73% |
| 2018-12-31 | $6.92 Million | $-2.89 Million | -0.417x | -52.76% |
| 2017-12-31 | $9.62 Million | $-2.63 Million | -0.273x | +35.27% |
| 2016-12-31 | $2.83 Million | $-1.19 Million | -0.422x | -82.64% |
| 2015-12-31 | $2.75 Million | $-636.33K | -0.231x | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more